Form 8-K - Current report:
SEC Accession No. 0001641172-25-011868
Filing Date
2025-05-21
Accepted
2025-05-21 08:45:32
Documents
12
Period of Report
2025-05-19
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39778
  Complete submission text file 0001641172-25-011868.txt   207358

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE telo-20250519.xsd EX-101.SCH 3030
3 XBRL LABEL FILE telo-20250519_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE telo-20250519_pre.xml EX-101.PRE 22369
14 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3788
Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41952 | Film No.: 25970992
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)